Wall Street brokerages expect Chromadex Corp (NASDAQ:CDXC) to announce earnings per share (EPS) of ($0.10) for the current quarter, Zacks reports. Three analysts have provided estimates for Chromadex’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.07). Chromadex posted earnings of ($0.08) per share during the same quarter last year, which would indicate a negative year over year growth rate of 25%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 10th.
On average, analysts expect that Chromadex will report full year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.30). For the next year, analysts forecast that the company will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.26) to ($0.04). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Chromadex.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. Chromadex had a negative return on equity of 103.66% and a negative net margin of 46.86%. The business had revenue of $15.29 million during the quarter, compared to analysts’ expectations of $13.56 million.
Shares of Chromadex stock traded down $0.14 during trading on Wednesday, reaching $4.09. 204,357 shares of the company were exchanged, compared to its average volume of 376,206. Chromadex has a twelve month low of $2.50 and a twelve month high of $5.80. The business has a 50-day moving average price of $4.85 and a 200-day moving average price of $4.46. The firm has a market capitalization of $260.67 million, a price-to-earnings ratio of -9.74 and a beta of 1.73.
Institutional investors have recently modified their holdings of the company. State Street Corp lifted its stake in Chromadex by 2.4% in the first quarter. State Street Corp now owns 698,422 shares of the company’s stock worth $2,277,000 after purchasing an additional 16,124 shares during the last quarter. Bessemer Group Inc. bought a new stake in Chromadex in the second quarter worth $532,000. BNP Paribas Arbitrage SA lifted its stake in Chromadex by 123.1% in the first quarter. BNP Paribas Arbitrage SA now owns 12,723 shares of the company’s stock worth $41,000 after purchasing an additional 7,019 shares during the last quarter. Geode Capital Management LLC lifted its stake in Chromadex by 17.8% in the first quarter. Geode Capital Management LLC now owns 587,632 shares of the company’s stock worth $1,915,000 after purchasing an additional 88,699 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Chromadex in the second quarter worth $102,000. Institutional investors own 22.93% of the company’s stock.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Featured Article: Why do company’s buyback their stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.